ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae

Michael R. Jacobs; Caryn E. Good; Andrea M. Hujer; Ayman M. Abdelhamed; Daniel D. Rhoads; Kristine M. Hujer; Susan D. Rudin; T. Nicholas Domitrovic; Lynn E. Connolly; Kevin M. Krause; Robin Patel; Cesar A. Arias; Barry N. Kreiswirth; Laura J. Rojas; Roshan D'Souza; Richard C. White; Lauren M. Brinkac; Kevin Nguyen; Indresh Singh; Derrick E. Fouts; David Van Duin; Robert A. Bonomo

doi:10.1128/AAC.00012-20

ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae

Michael R. Jacobs
, Caryn E. Good
, Andrea M. Hujer
, Ayman M. Abdelhamed
, Daniel D. Rhoads
, Kristine M. Hujer
, Susan D. Rudin
, T. Nicholas Domitrovic
, Lynn E. Connolly
, Kevin M. Krause
, Robin Patel
, Cesar A. Arias
, Barry N. Kreiswirth
, Laura J. Rojas
, Roshan D'Souza
, Richard C. White
, Lauren M. Brinkac
, Kevin Nguyen
, Indresh Singh
, Derrick E. Fouts

David Van Duin, Robert A. Bonomo

Case Western Reserve University
Louis Stokes Cleveland Department of Veterans Affairs Medical Center
Achaogen Inc.
Mayo Clinic Rochester, MN
University of Texas Health Science Center at Houston
Universidad El Bosque
J. Craig Venter Institute
University of North Carolina at Chapel Hill

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Plazomicin was tested against 697 recently acquired carbapenemresistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of>32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.

Original language	English
Article number	e00012-20
Journal	Antimicrobial Agents and Chemotherapy
Volume	64
Issue number	5
DOIs	https://doi.org/10.1128/AAC.00012-20
State	Published - May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Antibiotic resistance
Carbapenemase
Klebsiella
Plazomicin

Access to Document

10.1128/AAC.00012-20

Cite this

Jacobs, M. R., Good, C. E., Hujer, A. M., Abdelhamed, A. M., Rhoads, D. D., Hujer, K. M., Rudin, S. D., Domitrovic, T. N., Connolly, L. E., Krause, K. M., Patel, R., Arias, C. A., Kreiswirth, B. N., Rojas, L. J., D'Souza, R., White, R. C., Brinkac, L. M., Nguyen, K., Singh, I., ... Bonomo, R. A. (2020). ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 64(5), Article e00012-20. https://doi.org/10.1128/AAC.00012-20

@article{d34895a9c8f04df48bc53764550bbb35,

title = "ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae",

abstract = "Plazomicin was tested against 697 recently acquired carbapenemresistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6\%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3\%) intermediate (MICs of 4 mg/liter), and 8 (1.1\%) resistant (MICs of>32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.",

keywords = "Antibiotic resistance, Carbapenemase, Klebsiella, Plazomicin",

author = "Jacobs, \{Michael R.\} and Good, \{Caryn E.\} and Hujer, \{Andrea M.\} and Abdelhamed, \{Ayman M.\} and Rhoads, \{Daniel D.\} and Hujer, \{Kristine M.\} and Rudin, \{Susan D.\} and Domitrovic, \{T. Nicholas\} and Connolly, \{Lynn E.\} and Krause, \{Kevin M.\} and Robin Patel and Arias, \{Cesar A.\} and Kreiswirth, \{Barry N.\} and Rojas, \{Laura J.\} and Roshan D'Souza and White, \{Richard C.\} and Brinkac, \{Lauren M.\} and Kevin Nguyen and Indresh Singh and Fouts, \{Derrick E.\} and \{Van Duin\}, David and Bonomo, \{Robert A.\}",

note = "Publisher Copyright: {\textcopyright} 2020 American Society for Microbiology.",

year = "2020",

month = may,

doi = "10.1128/AAC.00012-20",

language = "English",

volume = "64",

journal = "Antimicrobial Agents and Chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

Jacobs, MR, Good, CE, Hujer, AM, Abdelhamed, AM, Rhoads, DD, Hujer, KM, Rudin, SD, Domitrovic, TN, Connolly, LE, Krause, KM, Patel, R, Arias, CA, Kreiswirth, BN, Rojas, LJ, D'Souza, R, White, RC, Brinkac, LM, Nguyen, K, Singh, I, Fouts, DE, Van Duin, D & Bonomo, RA 2020, 'ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae', Antimicrobial Agents and Chemotherapy, vol. 64, no. 5, e00012-20. https://doi.org/10.1128/AAC.00012-20

TY - JOUR

T1 - ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae

AU - Jacobs, Michael R.

AU - Good, Caryn E.

AU - Hujer, Andrea M.

AU - Abdelhamed, Ayman M.

AU - Rhoads, Daniel D.

AU - Hujer, Kristine M.

AU - Rudin, Susan D.

AU - Domitrovic, T. Nicholas

AU - Connolly, Lynn E.

AU - Krause, Kevin M.

AU - Patel, Robin

AU - Arias, Cesar A.

AU - Kreiswirth, Barry N.

AU - Rojas, Laura J.

AU - D'Souza, Roshan

AU - White, Richard C.

AU - Brinkac, Lauren M.

AU - Nguyen, Kevin

AU - Singh, Indresh

AU - Fouts, Derrick E.

AU - Van Duin, David

AU - Bonomo, Robert A.

PY - 2020/5

Y1 - 2020/5

N2 - Plazomicin was tested against 697 recently acquired carbapenemresistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of>32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.

AB - Plazomicin was tested against 697 recently acquired carbapenemresistant Klebsiella pneumoniae isolates from the Great Lakes region of the United States. Plazomicin MIC50 and MIC90 values were 0.25 and 1 mg/liter, respectively; 680 isolates (97.6%) were susceptible (MICs of ≤2 mg/liter), 9 (1.3%) intermediate (MICs of 4 mg/liter), and 8 (1.1%) resistant (MICs of>32 mg/liter). Resistance was associated with rmtF-, rmtB-, or armA-encoded 16S rRNA methyltransferases in all except 1 isolate.

KW - Antibiotic resistance

KW - Carbapenemase

KW - Klebsiella

KW - Plazomicin

UR - https://www.scopus.com/pages/publications/85083703021

U2 - 10.1128/AAC.00012-20

DO - 10.1128/AAC.00012-20

M3 - Article

C2 - 32152078

AN - SCOPUS:85083703021

SN - 0066-4804

VL - 64

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

IS - 5

M1 - e00012-20

ER -

ARGONAUT II study of the in vitro activity of plazomicin against carbapenemase-producing klebsiella pneumoniae

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this